Immutep reports strong response rate from immunotherapies treating carcinomas
Biotechnology company Immutep Ltd (ASX:IMM) which is developing novel LAG-3 immunotherapies for…
Immutep Limited (ASX:IMM)
About Immutep Limited
Key Information
IMM In the News
ASX Announcements
| Date | Announcement | File | Views |
|---|---|---|---|
| 26/07/2024 | Change in substantial holding | 623.25KB | 1.3K |
| 22/07/2024 | Price Sensitive PS Successful Meeting with FDA on Phase III Design in NSCLC | 240.17KB | 8.6K |
| 17/07/2024 | Price Sensitive PS Regulatory Clearance received for Phase 1 trial of IMP761 | 266.83KB | 6.4K |
| 12/07/2024 | Becoming a substantial holder | 256.59KB | 683 |
| 12/07/2024 | Price Sensitive PS Positive results in TACTI-003 for 1L HNSCC cohort B patients | 247KB | 20K |
| 12/07/2024 | Price Sensitive PS Webcast to discuss data presented at ESMO Plenary Session | 934.44KB | 1.2K |
| 04/07/2024 | Change in substantial holding | 459.85KB | 2.4K |
| 03/07/2024 | Details for Immutep Webcast & ESMO Virtual Plenary Session | 242.98KB | 10K |